|Title:||Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: A nested case-control study||Authors:||Chang C.-H.
|Issue Date:||2016||Publisher:||Lippincott Williams and Wilkins||Journal Volume:||34||Journal Issue:||3||Start page/Pages:||558-566||Source:||Journal of Hypertension||Abstract:||
Objective: The study aimed to investigate the association of long-term use of different antihypertensive agents with incident breast cancer. Methods: A total of 794533 women aged at least 55 years were identified from Taiwan National Health Insurance claims database during 2001-2011. As of 31 December 2011, incident breast cancer patients were included as cases, and 1:4 age-matched controls were selected by risk-set sampling scheme. Logistic regression models were applied to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) of breast cancer incidence associated with different durations of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and dihydropyridine calcium channel blockers (DHP CCBs). Different restriction rules were applied to reveal the potential effects of confounding by indication. Results: Among the 9397 incident breast cancer patients and 37588 controls, a significantly elevated risk was found for relatively short-term use of DHP CCBs (<6 years) but not in those observed for more than 6 years. There was no association between either angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or β-blockers use and breast cancer. Although restricting our analyses to those with any prescription of antihypertensive medications in 2001 or those with diagnosis of hypertension, there was no longer a statistically significant association between any use of DHP CCBs and breast cancer (OR: 1.21, 95% CI: 0.88-1.67 for the former, and OR: 1.71, 95% CI: 0.99-2.95 for the latter). Conclusion: The results demonstrated the potential effect of confounding by indication, and thus, did not suggest any association of the use of antihypertensive medication and breast cancer risk. ? Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
|ISSN:||0263-6352||DOI:||10.1097/HJH.0000000000000813||metadata.dc.subject.other:||angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; dihydropyridine; dipeptidyl carboxypeptidase inhibitor; antihypertensive agent; dihydropyridine derivative; adult; Article; breast cancer; cancer incidence; cancer risk; case control study; controlled study; disease association; disease duration; drug effect; drug indication; drug use; female; high risk patient; hormone substitution; human; hypertension; long term care; major clinical study; middle aged; prescription; priority journal; risk assessment; risk factor; short course therapy; aged; Breast Neoplasms; hypertension; incidence; odds ratio; statistical model; Taiwan; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Breast Neoplasms; Calcium Channel Blockers; Case-Control Studies; Dihydropyridines; Female; Humans; Hypertension; Incidence; Logistic Models; Middle Aged; Odds Ratio; Risk Factors; Taiwan
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.